Tapentadol for Neuropathic Pain: a Review of Clinical Studies

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2019 Jun 14

PMID 31190965

Citations 19

Authors

Ulderico Freo

Patrizia Romualdi

Hans G Kress

Affiliations

Soon will be listed here.

Abstract

Neuropathic pain (NP) is an enormous burden for patients, caregivers and society. NP is a pain state that may develop after injury of the peripheral or central nervous system because of a wide range of diseases and traumas. A NP symptom component can be found also in several types of chronic pain. Many NP patients are substantially disabled for years. Due to its chronicity, severity and unpredictability, NP is difficult to treat. Tapentadol is a central-acting oral analgesic with combined opioid and noradrenergic properties, which make it potentially suitable for a wide range of pain conditions, particularly whenever a NP component is present or cannot be excluded. In randomized controlled trials, tapentadol has proved to be effective in relieving NP in diabetic peripheral neuropathy and in chronic low back pain. In observational studies, tapentadol reduced NP in chemotherapy-induced peripheral neuropathies, blood and solid cancers, and the NP component in neck pain and Parkinson's disease. This narrative review aims to provide clinicians with a broad overview of tapentadol effects on NP.

Citing Articles

Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.

Manengu C, Zhu C, Zhang G, Tian M, Lan X, Tao L Curr Neuropharmacol. 2024; 23(3):276-294.

PMID: 39411936 PMC: 11808587. DOI: 10.2174/1570159X23666241011163035.

Opioid system and related ligands: from the past to future perspectives.

Rullo L, Morosini C, Lacorte A, Cristani M, Coluzzi F, Candeletti S J Anesth Analg Crit Care. 2024; 4(1):70.

PMID: 39390585 PMC: 11468104. DOI: 10.1186/s44158-024-00201-2.

Sex-Gender Differences Are Completely Neglected in Treatments for Neuropathic Pain.

Salis F, Sardo S, Finco G, Gessa G, Franconi F, Agabio R Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065689 PMC: 11280170. DOI: 10.3390/ph17070838.

Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.

Bhrigu B, Sharma S, Kumar N, Banik B Curr Diabetes Rev. 2024; 21(6):12-31.

PMID: 38798207 DOI: 10.2174/0115733998290606240521113832.

Pharmacological Treatments and Therapeutic Drug Monitoring in Patients with Chronic Pain.

De Rosa F, Giannatiempo B, Charlier B, Coglianese A, Mensitieri F, Gaudino G Pharmaceutics. 2023; 15(8).

PMID: 37631302 PMC: 10457775. DOI: 10.3390/pharmaceutics15082088.

References

Fishbain D, Cole B, Lewis J, Gao J . What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2013; 15(1):4-15. DOI: 10.1111/pme.12229. View

Schwartz S, Etropolski M, Shapiro D, Okamoto A, Lange R, Haeussler J . Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2010; 27(1):151-62. DOI: 10.1185/03007995.2010.537589. View

Pergolizzi J, Alon E, Baron R, Bonezzi C, Dobrogowski J, Galvez R . Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?. J Pain Res. 2011; 4:203-10. PMC: 3160833. DOI: 10.2147/JPR.S19625. View

Coluzzi F, Raffa R, Pergolizzi J, Rocco A, Locarini P, Cenfra N . Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015; 8:229-38. PMC: 4431495. DOI: 10.2147/JPR.S83490. View

Baron R, Kennes L, Elling C . Retrospective analyses versus RCTs: comparing like with like?. J Pain Res. 2017; 10:783-786. PMC: 5386600. DOI: 10.2147/JPR.S133369. View

Moriarty O, Ruane N, OGorman D, Maharaj C, Mitchell C, Sarma K . Cognitive Impairment in Patients with Chronic Neuropathic or Radicular Pain: An Interaction of Pain and Age. Front Behav Neurosci. 2017; 11:100. PMC: 5468384. DOI: 10.3389/fnbeh.2017.00100. View

Reichling D, Levine J . Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011; 69(1):13-21. DOI: 10.1002/ana.22351. View

French H, Smart K, Doyle F . Prevalence of neuropathic pain in knee or hip osteoarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017; 47(1):1-8. DOI: 10.1016/j.semarthrit.2017.02.008. View

Stocks J, Tang N, Walsh D, Warner S, Harvey H, Jenkins W . Bidirectional association between disturbed sleep and neuropathic pain symptoms: a prospective cohort study in post-total joint replacement participants. J Pain Res. 2018; 11:1087-1093. PMC: 5997123. DOI: 10.2147/JPR.S149830. View

10.

Imanaka K, Tominaga Y, Etropolski M, Van Hove I, Ohsaka M, Wanibe M . Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013; 29(10):1399-409. DOI: 10.1185/03007995.2013.831816. View

11.

Tzschentke T, Christoph T, Kogel B, Schiene K, Hennies H, Englberger W . (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1):265-76. DOI: 10.1124/jpet.107.126052. View

12.

Ford B . Pain in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S98-103. DOI: 10.1002/mds.22716. View

13.

Brefel-Courbon C, Grolleau S, Thalamas C, Bourrel R, Allaria-Lapierre V, Loi R . Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Pain. 2008; 141(1-2):14-8. DOI: 10.1016/j.pain.2008.04.026. View

14.

Addington J, Freimer M . Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res. 2016; 5. PMC: 4920214. DOI: 10.12688/f1000research.8053.1. View

15.

Kress H . Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?. Eur J Pain. 2010; 14(8):781-3. DOI: 10.1016/j.ejpain.2010.06.017. View

16.

Tominaga Y, Koga H, Uchida N, Wanibe M, Hirose K, Matsumura T . Methodological Issues in Conducting Pilot Trials in Chronic Pain as Randomized, Double-blind, Placebo-controlled Studies. Drug Res (Stuttg). 2016; 66(7):363-70. DOI: 10.1055/s-0042-107669. View

17.

Selvarajah D, Wilkinson I, Davies J, Gandhi R, Tesfaye S . Central nervous system involvement in diabetic neuropathy. Curr Diab Rep. 2011; 11(4):310-22. DOI: 10.1007/s11892-011-0205-z. View

18.

Attal N, Bouhassira D . Can pain be more or less neuropathic?. Pain. 2005; 110(3):510-511. DOI: 10.1016/j.pain.2004.06.0194. View

19.

Chio A, Mora G, Lauria G . Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2016; 16(2):144-157. DOI: 10.1016/S1474-4422(16)30358-1. View

20.

Bortolotto V, Grilli M . Opiate Analgesics as Negative Modulators of Adult Hippocampal Neurogenesis: Potential Implications in Clinical Practice. Front Pharmacol. 2017; 8:254. PMC: 5422555. DOI: 10.3389/fphar.2017.00254. View